Aktis Oncology Statistics
Total Valuation
Aktis Oncology has a market cap or net worth of $1.37 billion. The enterprise value is $842.32 million.
| Market Cap | 1.37B |
| Enterprise Value | 842.32M |
Important Dates
The next estimated earnings date is Tuesday, August 18, 2026, before market open.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aktis Oncology has 55.28 million shares outstanding. The number of shares has increased by 1,784.33% in one year.
| Current Share Class | 53.40M |
| Shares Outstanding | 55.28M |
| Shares Change (YoY) | +1,784.33% |
| Shares Change (QoQ) | +5,750.69% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 44.79% |
| Float | 28.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 165.42 |
| Forward PS | 155.01 |
| PB Ratio | 2.71 |
| P/TBV Ratio | 2.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 101.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.49, with a Debt / Equity ratio of 0.02.
| Current Ratio | 19.49 |
| Quick Ratio | 19.37 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -13.61% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $104,772 |
| Profits Per Employee | -$849,000 |
| Employee Count | 79 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 24.37 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 53.41 |
| Average Volume (20 Days) | 272,306 |
Short Selling Information
The latest short interest is 3.74 million, so 6.77% of the outstanding shares have been sold short.
| Short Interest | 3.74M |
| Short Previous Month | 3.31M |
| Short % of Shares Out | 6.77% |
| Short % of Float | 13.29% |
| Short Ratio (days to cover) | 5.92 |
Income Statement
In the last 12 months, Aktis Oncology had revenue of $8.28 million and -$67.07 million in losses. Loss per share was -$5.25.
| Revenue | 8.28M |
| Gross Profit | -63.35M |
| Operating Income | -79.25M |
| Pretax Income | -67.07M |
| Net Income | -67.07M |
| EBITDA | -72.36M |
| EBIT | -74.68M |
| Loss Per Share | -$5.25 |
Balance Sheet
The company has $538.48 million in cash and $11.58 million in debt, with a net cash position of $526.91 million or $9.53 per share.
| Cash & Cash Equivalents | 538.48M |
| Total Debt | 11.58M |
| Net Cash | 526.91M |
| Net Cash Per Share | $9.53 |
| Equity (Book Value) | 506.11M |
| Book Value Per Share | 9.16 |
| Working Capital | 516.03M |
Cash Flow
In the last 12 months, operating cash flow was -$70.89 million and capital expenditures -$9.55 million, giving a free cash flow of -$80.43 million.
| Operating Cash Flow | -70.89M |
| Capital Expenditures | -9.55M |
| Depreciation & Amortization | 2.50M |
| Net Borrowing | n/a |
| Free Cash Flow | -80.43M |
| FCF Per Share | -$1.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | -957.44% |
| Pretax Margin | -810.33% |
| Profit Margin | n/a |
| EBITDA Margin | -1,113.67% |
| EBIT Margin | -1,149.52% |
| FCF Margin | n/a |
Dividends & Yields
Aktis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,784.33% |
| Shareholder Yield | -1,784.33% |
| Earnings Yield | -4.90% |
| FCF Yield | -5.87% |
Analyst Forecast
The average price target for Aktis Oncology is $34.38, which is 38.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.38 |
| Price Target Difference | 38.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 11.47% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aktis Oncology has an Altman Z-Score of 8.88 and a Piotroski F-Score of 2.
| Altman Z-Score | 8.88 |
| Piotroski F-Score | 2 |